Novo Nordisk CSO: Hemophilia Treatment ‘Segmenting’ Much Like In Diabetes

 
• By Sten Stovall
Factor VIII
Novo Nordisk CSO Comments Come As FDA Approves Long-Acting Factor VIII replacement therapy Esperoct • Source: Shutterstock

More from New Products

More from Scrip